<DOC>
	<DOCNO>NCT00027989</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness combine liposomal doxorubicin gemcitabine treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Gemcitabine Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate woman metastatic breast cancer treat doxorubicin HCl liposome gemcitabine . - Determine duration response , time disease progression , duration survival patient treat regimen . - Determine quality life patient treat regimen . - Determine quantitative toxicity regimen , term incidence , type , severity , patient . OUTLINE : This multicenter study . Patients receive doxorubicin HCl liposome IV 1 hour day 1 gemcitabine IV 30 minute day 1 8 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 course beyond documentation CR . Quality life assess baseline , day 1 course , end study . Patients follow 4 week every 3 month 5 year . PROJECTED ACCRUAL : A total 75 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic breast cancer Measurable disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 60100 % Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Absolute neutrophil count least 1,500/mm^3 No impaired bone marrow function Hepatic : Bilirubin great 2 mg/dL AST ALT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN ( unless attribute tumor ) No impaired hepatic function Renal : Creatinine great 2.5 mg/dL OR Creatinine clearance least 60 mL/min No impair renal function Cardiovascular : No prior cardiac disease within past 5 year OR LVEF least 50 % Other : No prior uncontrolled seizures No uncontrolled systemic infection No anthracycline resistance No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior trastuzumab ( Herceptin ) Chemotherapy : Prior adjuvant therapy anthracycline 320 mg/m^2 allow Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 1/3 hematopoietic site Surgery : Not specify Other : At least 30 day since prior investigational medication recover No 1 prior treatment regimen metastatic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>